preliminary results from keynote-055: pembrolizumab in hnscc
Published 7 years ago • 206 plays • Length 4:46Download video MP4
Download video MP3
Similar videos
-
5:00
keynote-055:pembrolizumab in hnscc
-
1:41
dr. bauml on keynote-055 study for patients with hnscc
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
3:07
the keynote-001 trial: a breakthrough for pembrolizumab
-
2:46
keynote-427 updates: first-line pembrolizumab monotherapy in patients with advanced clear cell r...
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
7:16
epacadostat plus pembrolizumab in patients with scchn: preliminary results from echo-202/keynote-037
-
7:19
keynote-555: pembrolizumab bioavailability after subcutaneous administration in melanoma
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
1:16
dr. mehra on keynote-012 results of pembrolizumab in head and neck cancer
-
2:04
preliminary results from the blin01 trial
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
6:32
latest results from keynote-181: pembrolizumab versus chemotherapy as a second-line therapy for ...
-
13:50
keynote 057 - pre test, post test and further readings
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
6:35
pembrolizumab as first-line therapy for recurrent/metastatic head and neck cancer
-
1:34
keynote-028: phase 1b trial of pembrolizumab in pd-l1-positive nasopharyngeal carcinoma